Mind The Maturity Gap: Medtechs Must Improve Digital And Omnichannel Uptake
Executive Summary
Boston Consulting Group began writing the third iteration of its report on next-generation commercial models to meet evolving medtech customer needs before COVID struck. But it findings and recommendations were even more relevant once the report – dubbed Milkman 3.0 ̶ was finally released in spring 2021, when learnings from the pandemic were being factored in by the medtech industry.
You may also be interested in...
Medtechs Told: Change Commercial Models Or Be Left Behind
Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.